Fast and Furious: changing gears on the road to cure with chimeric antigen receptor T cells in multiple myeloma
Authors:
Open Access
- 6 July 2024
- journal article
- research article
- Published by Elsevier in Seminars in Hematology
- Vol. 61 (5) , 306-313
Abstract
No abstract availableKeywords
This publication has 85 references indexed in Scilit:
- Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With TalquetamabClinical Lymphoma Myeloma and Leukemia, 2024
- Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in MyelomaTransplantation and Cellular Therapy, 2023
- Anti‐CD19 and anti‐BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem‐cell transplantation for high‐risk newly diagnosed multiple myelomaAmerican Journal of Hematology, 2022
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyThe Lancet, 2021
- Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7Molecular Therapy, 2021
- Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trialsThe Lancet Haematology, 2020
- A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trialThe Lancet Haematology, 2019
- The role of surface molecule CD229 in Multiple MyelomaClinical Immunology, 2019
- A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity OptimizationMolecular Therapy, 2017
- A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma.The EMBO Journal, 1992